Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases

Official record

Identifier

NCT07727083

Recruiting locations

country

China

Interventions studied

Not provided in the official record

Lead sponsor

Rong Tao

Target enrolment

1500 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Recruiting

First posted

Jul 27, 2026

Last updated on the registry

Aug 13, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Age 18 years or older.
* Newly diagnosed Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease meeting World Health Organization diagnostic criteria.
* For the retrospective cohort: diagnosis of extranodal NK/T-cell lymphoma between January 1, 2017 and December 31, 2025 at a participating center.
* For the prospective cohort: diagnosis between June 1, 2026 and December 31, 2030 of one of the following:
* Extranodal NK/T-cell lymphoma;
* Aggressive NK-cell leukemia;
* Systemic chronic active Epstein-Barr virus disease of T/NK-cell type; or Epstein-Barr virus-positive nodal T/NK-cell lymphoma.
* Availability of essential diagnostic, staging, and treatment information.
* For the prospective cohort: written informed consent and successful collection of the protocol-required baseline peripheral blood specimen.

Exclusion Criteria:

* For the retrospective cohort: no usable survival follow-up information, inability to confirm survival status, or inability to calculate the principal survival outcomes.
* For the prospective cohort: unwillingness or inability to participate in protocol-defined longitudinal clinical follow-up.

Indexed under

Lymphoma